Diagnosis and treatment of chronic hepatitis B and D. National consensus guideline in Hungary from 15 October 2016
Diagnosis and treatment of HBV/HDV infection means for the patient to be able to maintain working capacity, to increase quality of life, to prevent cancer, and to prolong life expectancy, while society benefits from eliminating the chances of further transmission of the viruses, and decreasing the overall costs of serious complications. The guideline delineates the treatment algorithms for 2017 set by a consensus meeting of physicians involved in the treatment of these diseases. The prevalence of HBV infection in the Hungarian general population is 0.5-0.7%. The indications of treatment is based upon viral examinations (including viral nucleic acid determination), determinations of disease activity and stage (including biochemical, pathologic, and/or non-invasive methods), and excluding contraindications. To avoid unnecessary side effects and for cost-effective approach the guideline stresses the importance of quick and detailed virologic evaluations, the applicability of elastography as an acceptable alternative of liver biopsy in this regard, as well as the relevance of appropriate consistent follow up schedule for viral response during therapy. The first choice of therapy in chronic hepatitis B infection can be pegylated interferon for 48 weeks or continuous entecavir or tenofovir therapy. The latter two must be continued for at least 12 months after hepatitis B surface antigen seroconversion. Adefovir dipivoxil is recommended mainly in combination therapy. Lamivudine is no longer a first choice; patients currently taking lamivudine must switch if response is inadequate. Appropriate treatment of patients taking immunosuppressive medications is highly recommended. Pegylated interferon based therapy is recommended for the treatment of concomitant hepatitis D infection. Orv. Hetil., 2017, 158(Suppl. 1) 23-35.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:158 |
|---|---|
| Enthalten in: |
Orvosi hetilap - 158(2017), Suppl 1 vom: 01. Feb., Seite 23-35 |
| Sprache: |
Ungarisch |
|---|
| Weiterer Titel: |
A hepatitis B- és D-vírus-fertőzés diagnosztikája, antivirális kezelése. Magyar konszenzusajánlás. Érvényes: 2016. október 15-től |
|---|
| Beteiligte Personen: |
Horváth, Gábor [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.07.2019 Date Revised 02.07.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1556/650.2017.30689 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM26913350X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM26913350X | ||
| 003 | DE-627 | ||
| 005 | 20231224223958.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||hun c | ||
| 024 | 7 | |a 10.1556/650.2017.30689 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0897.xml |
| 035 | |a (DE-627)NLM26913350X | ||
| 035 | |a (NLM)28218868 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a hun | ||
| 100 | 1 | |a Horváth, Gábor |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diagnosis and treatment of chronic hepatitis B and D. National consensus guideline in Hungary from 15 October 2016 |
| 246 | 3 | 3 | |a A hepatitis B- és D-vírus-fertőzés diagnosztikája, antivirális kezelése. Magyar konszenzusajánlás. Érvényes: 2016. október 15-től |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.07.2019 | ||
| 500 | |a Date Revised 02.07.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Diagnosis and treatment of HBV/HDV infection means for the patient to be able to maintain working capacity, to increase quality of life, to prevent cancer, and to prolong life expectancy, while society benefits from eliminating the chances of further transmission of the viruses, and decreasing the overall costs of serious complications. The guideline delineates the treatment algorithms for 2017 set by a consensus meeting of physicians involved in the treatment of these diseases. The prevalence of HBV infection in the Hungarian general population is 0.5-0.7%. The indications of treatment is based upon viral examinations (including viral nucleic acid determination), determinations of disease activity and stage (including biochemical, pathologic, and/or non-invasive methods), and excluding contraindications. To avoid unnecessary side effects and for cost-effective approach the guideline stresses the importance of quick and detailed virologic evaluations, the applicability of elastography as an acceptable alternative of liver biopsy in this regard, as well as the relevance of appropriate consistent follow up schedule for viral response during therapy. The first choice of therapy in chronic hepatitis B infection can be pegylated interferon for 48 weeks or continuous entecavir or tenofovir therapy. The latter two must be continued for at least 12 months after hepatitis B surface antigen seroconversion. Adefovir dipivoxil is recommended mainly in combination therapy. Lamivudine is no longer a first choice; patients currently taking lamivudine must switch if response is inadequate. Appropriate treatment of patients taking immunosuppressive medications is highly recommended. Pegylated interferon based therapy is recommended for the treatment of concomitant hepatitis D infection. Orv. Hetil., 2017, 158(Suppl. 1) 23-35 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a adefovir | |
| 650 | 4 | |a cirrhosis | |
| 650 | 4 | |a entecavir | |
| 650 | 4 | |a hepatitis B virus | |
| 650 | 4 | |a hepatitis B-vírus | |
| 650 | 4 | |a hepatitis D virus | |
| 650 | 4 | |a hepatitis D-vírus | |
| 650 | 4 | |a interferon | |
| 650 | 4 | |a lamivudin | |
| 650 | 4 | |a lamivudine | |
| 650 | 4 | |a liver cancer | |
| 650 | 4 | |a májrák | |
| 650 | 4 | |a májzsugor | |
| 650 | 4 | |a pegilált interferon | |
| 650 | 4 | |a pegylated interferon | |
| 650 | 4 | |a tenofovir | |
| 650 | 4 | |a viral hepatitis | |
| 650 | 4 | |a vírushepatitis | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Interferon-alpha |2 NLM | |
| 700 | 1 | |a Gerlei, Zsuzsanna |e verfasserin |4 aut | |
| 700 | 1 | |a Gervain, Judit |e verfasserin |4 aut | |
| 700 | 1 | |a Lengyel, Gabriella |e verfasserin |4 aut | |
| 700 | 1 | |a Makara, Mihály |e verfasserin |4 aut | |
| 700 | 1 | |a Pár, Alajos |e verfasserin |4 aut | |
| 700 | 1 | |a Rókusz, László |e verfasserin |4 aut | |
| 700 | 1 | |a Szalay, Ferenc |e verfasserin |4 aut | |
| 700 | 1 | |a Tornai, István |e verfasserin |4 aut | |
| 700 | 1 | |a Werling, Klára |e verfasserin |4 aut | |
| 700 | 1 | |a Hunyady, Béla |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Orvosi hetilap |d 1949 |g 158(2017), Suppl 1 vom: 01. Feb., Seite 23-35 |w (DE-627)NLM000021601 |x 1788-6120 |7 nnns |
| 773 | 1 | 8 | |g volume:158 |g year:2017 |g number:Suppl 1 |g day:01 |g month:02 |g pages:23-35 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1556/650.2017.30689 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 158 |j 2017 |e Suppl 1 |b 01 |c 02 |h 23-35 | ||